# Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

Source: https://onco.cc/trials/nct06899061/  
OnCo record `nct06899061` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is active not recruiting.

## Summary

The registry lists NCT06899061 as active not recruiting, last updated 2026-10-01. Enrolment is 41 actual participants. Interventions: Saruparib, Digoxin, Furosemide, Metformin Hydrochloride, Rosuvastatin, Rabeprazole. Primary measures include Module 1: Area under plasma concentration-time curve from zero extrapolated to infinity (AUCinf) of digoxin, furosemide, metformin and rosuvastatin when dosed alone and in combination with saruparib; Module 1: Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast) of digoxin, furosemide, metformin and rosuvastatin when dosed alone and in combination with saruparib. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-06
- Registry id: NCT06899061
- Phase: 1
- Setting: A Modular Phase I, Open-label Study to Assess the Safety, Pharmacokinetics, and Drug Interaction Potential and Relative Bioavailability of Saruparib in Patients With Advanced Solid Malignancies
- Sponsor: AstraZeneca
- Enrolled: 41

## Sources

- ClinicalTrials.gov NCT06899061: https://clinicaltrials.gov/study/NCT06899061

## Connected records

- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Saruparib](https://onco.cc/drugs/saruparib/)

---
JSON: https://onco.cc/api/v1/entities/nct06899061.json